Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. - Wikidata - awgldk - TriplyDB

Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease.

Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease.

http://www.wikidata.org/entity/Q44118287

about

Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis A role for Th17 cells in the regulation of tertiary lymphoid follicles Targeting TNF receptors in rheumatoid arthritis Lymphotoxin and TNF: how it all began-a tribute to the travelers In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-disease Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration.Dimerization of LT R by LT 1 2 is necessary and sufficient for signal transduction Potential of Cells and Cytokines/Chemokines to Regulate Tertiary Lymphoid Structures in Human Diseases Ectopic Tertiary Lymphoid Tissue in Inflammatory Bowel Disease: Protective or Provocateur?The IL-17 pathway as a major therapeutic target in autoimmune diseases Resurrection of a clinical antibody: template proteogenomic de novo proteomic sequencing and reverse engineering of an anti-lymphotoxin-α antibody.Innate lymphoid cells facilitate NK cell development through a lymphotoxin-mediated stromal microenvironment Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection.Th17 cells and activated dendritic cells are increased in vitiligo lesions Burn wound γδ T-cells support a Th2 and Th17 immune response Lymphotoxin-alpha contributes to lymphangiogenesis.SEF/IL-17R (SEFIR) is not enough: an extended SEFIR domain is required for il-17RA-mediated signal transduction.Lymphotoxin, NF-ĸB, and cancer: the dark side of cytokines.Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling.The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients.LTβR signaling in dendritic cells induces a type I IFN response that is required for optimal clonal expansion of CD8+ T cells.Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.Toll-like receptors expressed by synovial fibroblasts perpetuate Th1 and th17 cell responses in rheumatoid arthritis.The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy.TNF superfamily in inflammatory disease: translating basic insights.Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs.Placenta suppresses experimental autoimmune hypophysitis through soluble TNF receptor 1 Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases.Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.Human umbilical cord mesenchymal stem cells as treatment of adjuvant rheumatoid arthritis in a rat model Clinical targeting of the TNF and TNFR superfamilies Controlling herpetic stromal keratitis by modulating lymphotoxin-alpha-mediated inflammatory pathways.Long-term treatment of rheumatoid arthritis with adalimumab.Targeting lymphotoxin depletes pathogenic T cells Role of the Lymphotoxin/LIGHT System in the Development and Maintenance of Reticular Networks and Vasculature in Lymphoid Tissues Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions.

P2860

Q24604440-8E917700-A52B-4A07-9591-BD1ABCF693BC Q24612869-C2B090D2-165D-4E70-85FD-470569273E50 Q26851559-C5A4A925-E729-4161-B635-EDCD0486DA8A Q26853279-12278762-44B2-4FFE-AABE-F2D40EFFDC1B Q26865649-9AF73974-5D2F-4C31-B2F0-CD2F81A36F78 Q27307168-875F7A96-5B43-440C-BDB1-0DB174B4CABA Q27341886-76DF986A-4191-4F2B-8C0A-948654899851 Q27680632-91AB40B5-C0B9-4FB1-ACC1-7D65186C93DE Q28071670-D9D4D7A6-D0B1-4CF5-8C65-DEE587B4C99D Q28077990-DDEFC0FD-E264-418D-9B6B-79ED53F13B91 Q28300826-0066D374-B0C8-4760-85DF-0105CE5360B8 Q33804091-491C3EB1-2544-4BFC-8DA0-2A26AB672396 Q33826833-75BF38B8-C094-403A-AD61-22C087024FFA Q33883606-41F61117-6DC0-4A03-B497-B2BAE501BB1F Q33889471-4C2ED82C-CEF9-4CBA-9E27-80E621641373 Q33902749-DCB7208E-F188-4680-A9F2-1AE970D896E4 Q34184735-B0AE677A-3185-41B0-A3A3-6397ECE3585D Q34236471-7BF4A4D1-302A-4EE5-98A5-C20495581A80 Q34308847-1692B4E7-1AEB-4C7F-9297-A4A718744D5E Q34340648-D11D7505-942B-460D-A696-BA4FB80C2BC7 Q34544926-2EDCB96F-3894-48D9-B180-5A6A3F78E518 Q34549822-A329ACA0-7CB2-4F75-BB8B-DD22E8C720C1 Q34568533-C6229F87-093C-4526-98CA-7F8B409EBA92 Q34973492-72FC0718-5318-4A24-BE23-32C9367277C5 Q35080243-CDA2FC0A-B597-4B04-A0AC-C1E6C26C2E6D Q35189497-925496F9-D12A-44C6-9B0E-04AED543E0A5 Q35450066-F1368D2E-8D2F-4526-BB29-D5C59231323D Q35821666-014AA8A7-C03F-4290-9670-0FB9F63A1C1A Q35876885-EA63A63A-1F78-427C-8E72-E84CFFB8F369 Q36020169-09A60897-D028-4B95-A051-05DA755E6ED7 Q36084891-4C9C1AC0-FCA3-4CCB-9F9A-030D5B8204DA Q36219516-76C21EDE-0B36-4A9E-B288-E7784E3D1ADC Q36290143-7F11611D-FA0D-4226-AAEB-6945FC283681 Q36424891-5EEF9646-CD4C-485E-AE8F-5B41AAB53014 Q36762882-7E87484B-B8F4-4F27-8A0E-13493CB129CD Q37161210-30D0D533-55B9-46C9-A6EE-CF45C4B7B02F Q37358278-144C8D38-D86F-4287-B055-24047E6983F1 Q37377086-4DAAA3F7-7646-458A-8C7B-0F1F8E45C6D0 Q37576573-2D285A9D-A909-482E-B934-5A4FE17C0CAE Q37681821-709DD70E-D101-4735-B986-96F5A74E8824

P2860

Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease.

http://www.wikidata.org/entity/Q44118287

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Targeted depletion of lymphoto ...... s inhibits autoimmune disease.

@en

Targeted depletion of lymphoto ...... s inhibits autoimmune disease.

@nl

type

label

Targeted depletion of lymphoto ...... s inhibits autoimmune disease.

@en

Targeted depletion of lymphoto ...... s inhibits autoimmune disease.

@nl

prefLabel

Targeted depletion of lymphoto ...... s inhibits autoimmune disease.

@en

Targeted depletion of lymphoto ...... s inhibits autoimmune disease.

@nl

P1433

Q44118287-0EDFB5AF-5497-409F-AC32-A742978F8A9D

P1476

Q44118287-6151936C-75A6-4BF1-9D2D-0787BBABA95F

P2093

Q44118287-079674A0-613A-4C3A-B396-C6A062A3F692

Q44118287-0BF450A4-3D98-4B8B-A5AD-99E65BA5DF29

Q44118287-2F6DF8CF-2E50-401A-82DD-2CC6FC300E8E

Q44118287-3A53AC87-7F2D-4902-8944-635F6AE857C7

Q44118287-3E923213-A9E7-42C7-8645-B9765AC6308F

Q44118287-45E543B7-5879-4BD6-86B4-5816D356BDEA

Q44118287-50C6F590-F8CA-40BC-93FC-92D784F250D2

Q44118287-5274CD1F-BBAB-491C-974F-01AC2B9B8D43

Q44118287-62816741-71A2-481D-AA03-4574B4CC9DDE

Q44118287-6961A980-AEFC-453F-84EE-2C9A3EF71B26

P2860

Q44118287-0DB9E5C9-13CD-4E05-A7A8-884CC1F847B6

Q44118287-6633787F-134A-4686-BF88-F00A02CD1A6B

Q44118287-752DCBC3-AB88-431D-95ED-B949173C34ED

Q44118287-7ADCD508-9B6B-4BE8-84BD-4D45E6DF4906

Q44118287-CFB473EE-6004-4A12-AB2D-12F2C18EE4C7

P2888

Q44118287-81664C64-87AC-44C2-80B7-2F466A42E81B

P304

Q44118287-FE390472-3DCA-4B42-9F5E-DF64EBCB261B

P31

Q44118287-F3F8057A-0167-4154-B2F4-82CD591EF88E

P356

Q44118287-9FB88F64-80A7-45CE-8DD1-0FA850A894C2

P407

Q44118287-E700D8DD-F213-4873-A7D7-CDBEA493921A

P433

Q44118287-BEDE609C-D6B8-4F61-A821-16F14E9DD6DD

P478

Q44118287-66A792A7-040A-48D4-9679-7E63C34E1EED

P577

Q44118287-E5168E81-EACE-4C71-93BD-8B65B2B3C0B5

P698

Q44118287-2DA71188-F042-4ED6-A5FE-B36DAE947EBD

P356

P1433

Nature Medicine

P1476

Targeted depletion of lymphoto ...... s inhibits autoimmune disease.

@en

P2093

Allen Nguyen

http://www.w3.org/2001/XMLSchema#string

Andres Paler-Martinez

http://www.w3.org/2001/XMLSchema#string

Canio J Refino

http://www.w3.org/2001/XMLSchema#string

Devavani Chatterjea

http://www.w3.org/2001/XMLSchema#string

Eugene Y Chiang

http://www.w3.org/2001/XMLSchema#string

Ganesh A Kolumam

http://www.w3.org/2001/XMLSchema#string

Ivan Peng

http://www.w3.org/2001/XMLSchema#string

Jane L Grogan

http://www.w3.org/2001/XMLSchema#string

Jean Shu

http://www.w3.org/2001/XMLSchema#string

Judy Young

http://www.w3.org/2001/XMLSchema#string

P2860

A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT.

Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis

Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis.

Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion.

A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis.

P2888

P304

766-773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.1984

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19561618

http://www.w3.org/2001/XMLSchema#string